NNMDA Herbal Medicines Unveiled for Cancer
LAGOS — The Federal Government has unveiled a collection of locally developed herbal products targeting major health conditions, including hepatitis B, some cancers, hypertension, peptic ulcer disease and high cholesterol, as Nigeria intensifies efforts to transform indigenous medicinal knowledge into scientifically validated pharmaceutical products.
The products were developed by the Nigeria Natural Medicine Development Agency, an institution under the Federal Ministry of Innovation, Science and Technology. They were presented during an official visit to the agency’s Victoria Island headquarters in Lagos by the Minister of Innovation, Science and Technology, Dr Kingsley Udeh.
The unveiling of the NNMDA herbal medicines represents a potentially important step for local pharmaceutical research. It must, however, be reported with scientific caution: unveiling a product is not the same as proving through rigorous clinical trials that it can cure cancer or eliminate chronic hepatitis B.
Available reports do not disclose NAFDAC registration numbers, completed large-scale clinical-trial results or formal authorisation permitting the products to be promoted as established cures. Indeed, NNMDA’s Director-General, Professor Martins Emeje, called for greater investment in clinical trials and requested the establishment of a Clinical Observational Research Centre.
Six products publicly identified
The government described the event as the unveiling of seven herbal products, although only six names were clearly identified in the publicly available accounts.
They are Namdavir, developed for hepatitis B research; Namdacid, intended for the management of peptic ulcer disease; Turmegol, being studied in connection with colorectal, ovarian and prostate cancers; Namdorol, developed for high cholesterol and hypertension; Namgor, described as an aphrodisiac; and Zobo Tea, presented for hypertension management.
Neither of the detailed reports reviewed identified the seventh product by name. That omission should be clarified by the agency before a definitive commercial or clinical product list is published.
Emeje said Namdavir was developed from an indigenous medicinal plant and had shown activity against hepatitis B in the agency’s research. He described Namdacid as a product developed for peptic ulcer management.
The NNMDA chief also said Turmegol had demonstrated potential in agency studies to halt the progression of certain cancers or affect early cancer cells. These remain claims attributed to the agency and should not be converted into declarations of a proven cure without independently reviewed clinical evidence.
FG promises clinical research centre
The unveiling of the NNMDA herbal medicines was accompanied by a significant government commitment to strengthen the infrastructure required for scientific validation.
Udeh promised to support the creation of a Clinical Observational Research Centre at the agency’s Lagos headquarters. He said the ministry would explore alternative funding arrangements rather than wait for an allocation in the 2027 federal budget.
The proposed centre could provide a more structured environment for observing patients, collecting safety data, assessing possible side effects and determining whether products deliver measurable clinical benefits.
However, observational research alone cannot replace all phases of controlled clinical trials. Products intended for serious conditions such as cancer or chronic hepatitis B require carefully designed studies, clear dosage standards, reliable comparison groups, transparent data and independent regulatory review.
NAFDAC’s official services include product registration, clinical-trial applications, laboratory analysis, pharmacovigilance and a registered-products database. Consequently, commercialisation must proceed through the appropriate regulatory pathways rather than through public enthusiasm alone.
Indigenous knowledge meets pharmaceutical science
The NNMDA herbal medicines are part of a wider effort to apply modern pharmaceutical science to Nigeria’s traditional medical knowledge.
NNMDA says its work covers research, documentation, product development and the promotion of indigenous medicine for possible integration into national healthcare delivery. The agency lists cancer management, diabetes, neglected tropical diseases and general wellness among its core research areas.
Emeje said improvements in standardisation had enabled traditional preparations to be produced in measurable dosage forms such as capsules, tablets and syrups.
This development matters because one of the major weaknesses historically associated with unregulated herbal preparations is inconsistent dosage. Two products bearing the same name may differ considerably in plant species, concentration, contamination level or manufacturing quality.
Standardisation can help researchers determine what substances a product contains, the quantity administered and whether each manufactured batch is reasonably consistent.
Yet standardisation is only one stage. A product may be consistently manufactured and still require evidence that it is safe, effective and suitable for particular patients.
More than 22 products developed since 2023
NNMDA said it had developed more than 22 herbal products from Nigerian medicinal plants since 2023.
The agency’s research has reportedly covered malaria, sickle cell disease, diabetes, erectile dysfunction and other conditions in addition to the products presented during the Lagos event.
Udeh said Nigeria’s biodiversity and longstanding medicinal traditions could support a substantial local natural-medicine industry. He also met pharmaceutical-sector representatives to discuss possible commercialisation.
According to the minister, a stronger indigenous pharmaceutical industry could reduce dependence on imported medicines, generate revenue and create employment.
Emeje went further, saying one of the products could support as many as 3.5 million jobs if fully developed across its agricultural, manufacturing and commercial value chain. The report did not identify the methodology behind that projection, so it should be treated as an agency estimate rather than an independently verified employment forecast.
Scientific evidence must determine the next stage
The future of the NNMDA herbal medicines will depend less on the ceremony surrounding their unveiling than on the quality of the scientific evidence eventually produced.
Cancer is not a single disease. Colorectal, ovarian and prostate cancers have different biological features, treatment protocols and stages. A substance that shows activity against cells in a laboratory may not produce the same result safely in the human body.
Researchers must establish how a product is absorbed, how it interacts with the liver and kidneys, whether it interferes with chemotherapy or other medication, and whether it provides benefits greater than its risks.
The same caution applies to hepatitis B. The World Health Organisation says long-term antiviral therapy can effectively manage chronic hepatitis B and reduce the risk of severe liver disease. It also says vaccination protects more than 95 per cent of recipients against acute and chronic hepatitis B infection.
WHO reported that an estimated 240 million people were living with chronic hepatitis B in 2024, while fewer than five per cent were receiving treatment. Nigeria was among 10 countries accounting for 69 per cent of global hepatitis B-related deaths that year.
These figures demonstrate why new treatments are urgently needed. They also explain why unverified claims must be handled responsibly: people living with hepatitis B should not abandon medical monitoring or established treatment because a research product has been unveiled.
https://ogelenews.ng/nnmda-herbal-medicines
NAFDAC approval remains essential
The public presentation of the NNMDA herbal medicines should not be confused with market authorisation.
NAFDAC is responsible for ensuring that regulated products manufactured, imported, exported, distributed or sold in Nigeria meet applicable standards of quality and safety. Its processes include clinical-trial review, product registration, laboratory evaluation and post-market surveillance.
Before widespread use, each product should have a traceable regulatory status. The manufacturer, ingredients, indications, dosage, contraindications, warnings, storage requirements and possible adverse reactions should be clearly documented.
Where evidence supports only traditional use or limited preliminary research, promotional claims must reflect that limitation. A product should not be presented as curing a serious illness merely because it contains a medicinal plant or has demonstrated activity in an early-stage experiment.
Patients undergoing cancer treatment may be particularly vulnerable to exaggerated promises. Some herbal products can interact with prescribed medicines or affect liver function, blood clotting and treatment response.
Anyone considering an herbal preparation for a diagnosed condition should discuss it with a qualified healthcare professional and verify its registration status through NAFDAC’s official database.
India seeks research collaboration
The unveiling of the NNMDA herbal medicines also produced an offer of deeper cooperation between Nigeria and India.
India’s Consul General in Lagos, Shri Kannan, said both countries could collaborate in medicinal-plant research, scientific validation, quality assurance, biodiversity conservation, skills development, academic exchanges and innovation.
He argued that Nigeria and India possess longstanding healing traditions and extensive biological resources that could contribute to modern healthcare when supported by scientific research.
Such cooperation could strengthen laboratory capacity and help Nigeria learn from established systems for regulating traditional products. It must also protect local intellectual property and ensure that communities whose knowledge contributes to commercial medicines benefit fairly.
Researchers should document the origin of medicinal knowledge, obtain necessary consent and create transparent benefit-sharing arrangements where commercial products emerge from community practices.
Economic promise must not overshadow patient safety
The commercial potential attached to the NNMDA herbal medicines is considerable, but public health must remain the first priority.
Nigeria imports a significant share of its pharmaceutical products and raw materials. Developing credible local medicines could conserve foreign exchange, create agricultural and scientific jobs and improve access to treatment.
Nevertheless, commercial pressure must not encourage premature claims.
A credible pathway should include the identification of plant materials, laboratory testing, toxicity studies, standardised production, phased clinical trials, ethical approval, NAFDAC evaluation, peer-reviewed publication and continuous monitoring after approval.
The Federal Government should also publish the research evidence behind each product. Scientists outside NNMDA should be able to examine the methods, sample sizes, outcomes and limitations.
Transparency would strengthen rather than weaken public confidence. It would allow promising discoveries to gain legitimate acceptance and prevent ineffective products from being promoted on the strength of official ceremonies.
A promising beginning, not the final verdict
The unveiling of the NNMDA herbal medicines deserves recognition as evidence that Nigerian scientists are exploring the medicinal potential of the country’s biodiversity.
It also highlights the possibilities created when traditional knowledge, pharmaceutical research and industrial development are brought together.
But the ceremony should be regarded as the beginning of a demanding scientific and regulatory process, not its conclusion.
Nigeria will gain far more from producing a smaller number of internationally credible, clinically validated herbal medicines than from releasing numerous products without sufficient evidence.
The next questions are therefore unavoidable: Have the products completed the required clinical trials? Are they registered for the precise claims being made? What adverse reactions have been observed? Will the research data be published? When will the complete list of seven products be released?
Until those questions are answered, patients should continue relying on qualified medical advice and established treatment protocols.
The promise of indigenous medicine is real. Its lasting value, however, will be determined by evidence, regulation, transparency and patient safety.
